Sbir phase I: rapid repurposing and translation of COVID-19 therapeutics using a AI-based biosimulation platform: application to ACE2 and CA2+ multi-target therapies (COVID-19)

Ended Project Grant Awarded Last action

Award ID
2035834
Recipient
Awarding agency
Obligated
$255,908

Award facts

Assistance listing
47.041 Engineering
Completion date
Place of performance
San Francisco, CA 94104, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The National Science Foundation Division of Industrial Innovation awarded a $255,908 Project Grant to Verisim Life, Inc. under the Engineering (47.041) federal grant program. The grant supports Verisim Life's efforts to rapidly repurpose and translate COVID-19 therapeutics using an AI-based biosimulation platform. Specifically, the company will apply its platform to research multi-target therapies involving angiotensin-converting enzyme 2 and calcium pathways, which could help combat the COVID-19 pandemic. The one-year project period runs from January 15, 2021 through December 31, 2021. The focus of this award is to leverage advanced computational modeling and machine learning to efficiently identify promising drug candidates and accelerate their preclinical testing, with the goal of developing effective COVID-19 treatments.

Quick answers

Who received award 2035834?

2035834 was awarded to Verisim Life, Inc. by Division of Industrial Innovation (National Science Foundation) on January 15, 2021.

How much is award 2035834 worth?

$255,908 has been obligated on 2035834.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login